Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: ADMA

ADMA Biologics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for ADMA. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$0.70

ADMA Biologics, Inc. (NASDAQ: ADMA) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 06:00 UTC.

What ADMA Biologics, Inc. does

ADMA Biologics is a U.S. biopharmaceutical company that manufactures and markets specialty immune globulin products for immunodeficient and immunosuppressed patients. The company currently sells three FDA-approved products: ASCENIV and BIVIGAM for primary immunodeficiency treatment, and Nabi-HB for hepatitis B exposure. ADMA manufactures these products at its FDA-licensed plasma fractionation facility in Boca Raton, Florida, and operates plasma collection centers through its subsidiary ADMA BioCenters to secure raw materials and sell excess plasma to third parties.

Summarized from ADMA Biologics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$0.70
Return on equity30.78%
Debt/equity0.48

Revenue, margins & earnings

FY2021: net loss $72M on revenue $81M$81MFY2021FY2022: net loss $66M on revenue $154M$154MFY2022FY2023: net loss $28M on revenue $258M$258MFY2023FY2024 Revenue: $426M — margin split not shown (non-operating gains)$426MFY2024FY2025 Net income: $147MFY2025 Taxes & interest: $45MFY2025 Operating expenses: $101MFY2025 Cost of revenue: $217M$510MFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
  • Net loss year
Annual revenue; bands show net, operating, gross margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-07-28
  • 2026-07-28COO and SVP, ComplianceTax withholding-3,177$26.6K
  • 2026-07-17CFO and TreasurerStock Option (Right to Buy)Award136,363—
  • 2026-07-17CFO and TreasurerAward85,130—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does ADMA Biologics, Inc. do?

ADMA Biologics, Inc. is a biotechnology company, listed on NASDAQ as ADMA.

When did ADMA last file with the SEC?

ADMA Biologics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-02. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 06:00 UTC. This page is also available as JSON at /api/data?ticker=ADMA and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ADMA and 5,000+ tickers.

Create a free account — keep ADMA
For your agent
GET /api/data?ticker=ADMA

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt